<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59364">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333175</url>
  </required_header>
  <id_info>
    <org_study_id>14/0040</org_study_id>
    <nct_id>NCT02333175</nct_id>
  </id_info>
  <brief_title>Care for Late Stage Parkinsonism</brief_title>
  <acronym>CLaSP</acronym>
  <official_title>Care for Late Stage Parkinsonism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Medicina Molecular</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to evaluate the needs and provision of care for patients in the
      late stages of Parkinsonism and their carers in several European countries, to compare the
      effectiveness of different health and social care systems, and to lay the foundation for
      improved outcomes in this population. The investigators will undertake an in-depth
      assessment of patients and their care arrangements in a population recruited through
      networks in six European countries. The systems and procedures that are used in the
      provision of care will be reviewed through a systematic literature review, interviews and
      assessments of patients, carers and health care providers, and through a trial comparing
      assessment by a specialist with management suggestions, guidance and access to telephone
      advice to that of usual care. Through interviews, questionnaire assessment and review of
      current health-care and social care arrangement, the investigators will assess the needs,
      provision of care and use of health-care resources, and their impact on patient and carer
      outcomes in different countries. National and regional databases will also be interrogated
      to identify current practice and use of healthcare resources and drug usage. A systematic
      literature review of the evidence for effective management strategies, analysis of the study
      data, and evaluation of change in outcomes following specialist review will provide the
      basis for recommendations in the management of late stage Parkinsonism. The investigators
      will also evaluate potentially useful outcome measures for use in this patient group. In
      addition to charting the needs and current care provision for late stage Parkinsonism in
      different European countries, its cost and effectiveness, and an analysis of health-care and
      social care predictors of improved outcome, the project will produce a platform for the
      assessment of patients with late stage Parkinsonism, their current treatment and care
      provision, as well as guidelines on the management of this late disease phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UPDRS-ADL part</measure>
    <time_frame>6 months</time_frame>
    <description>Disability measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PDQ-8 or DEMQoL proxy</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zarit carer burden scale</measure>
    <time_frame>6 months</time_frame>
    <description>Carer burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with care Likert scale</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>6 months</time_frame>
    <description>Mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPI</measure>
    <time_frame>6 months</time_frame>
    <description>Mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS III</measure>
    <time_frame>6 months</time_frame>
    <description>PD severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NMSS</measure>
    <time_frame>6 months</time_frame>
    <description>PD severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD milestones</measure>
    <time_frame>6 months</time_frame>
    <description>PD severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic palliative care assessment</measure>
    <time_frame>6 months</time_frame>
    <description>ESAS-PD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Late Stage Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Specialist review</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Specialist review with individually tailored treatment strategies suggested by specialist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Care as usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Care as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specialist review</intervention_name>
    <description>Specialist review with individually tailored treatment strategies suggested by specialist</description>
    <arm_group_label>Specialist review</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hoehn and Yahr stage (HY) IV or V in the &quot;On&quot;-state

          -  Disease duration of at least 7 years

        Exclusion Criteria:

          -  Symptomatic Parkinsonism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anette Schrag, MD</last_name>
    <phone>00442077940500</phone>
    <phone_ext>36773</phone_ext>
    <email>a.schrag@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wassilios Meissner, MD PhD</last_name>
      <email>wassilios.meissner@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Wassilios Meissner, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Lorenzl, MD</last_name>
      <phone>0049-89-4400</phone>
      <phone_ext>77945</phone_ext>
      <email>stefan.lorenzl@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Richinger</last_name>
      <phone>0049-89-4400</phone>
      <phone_ext>77945</phone_ext>
      <email>carmen.richinger@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Georg NÃ¼bling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Balzer-Geldsetzer, MD</last_name>
      <phone>+49 6421 586 5607</phone>
      <email>monika.balzer@staff.uni-marburg.de</email>
    </contact>
    <contact_backup>
      <phone>+49 6421 586 6251</phone>
    </contact_backup>
    <investigator>
      <last_name>Richard Dodel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bas R Bloem, MD</last_name>
      <phone>+31 (0)243615202</phone>
      <email>bas.bloem@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marjan F Faber, PhD</last_name>
      <phone>+31 (0)243613114</phone>
      <email>marjan.faber@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Instituto de Medicina Molecular</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Coelho, MD</last_name>
      <phone>+351217930629</phone>
      <email>migcoelho2002@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Margherita Fabbri, MD</last_name>
      <phone>+351217930629</phone>
      <email>margheritafabbrimd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Miguel Coelho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joaquim Ferreira, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margherita Fabbri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catarina Godinho, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lund University</name>
      <address>
        <city>Lund</city>
        <zip>SE-22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per LA Odin, MD</last_name>
      <phone>+4646172729</phone>
      <email>per.odin@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Rosqvist, Physiotherapist</last_name>
      <phone>+4646172729</phone>
      <email>Kristina.Rosqvist@med.lu.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Schrag, MD</last_name>
      <phone>02077940500</phone>
      <phone_ext>34373</phone_ext>
      <email>a.schrag@ucl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Joy Read, MSc</last_name>
      <phone>02077940500</phone>
      <phone_ext>31218</phone_ext>
      <email>joy.read@ucl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Anette Schrag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>September 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease, Late stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
